Sigilon Therapeutics, a Phase 1/2 biotech developing allogeneic therapies for hemophilia A and diabetes, raised $126 million by offering 7 million shares at $18, within the range of $17 to $19. The company offered 1.4 million more shares than anticipated. At pricing, Sigilon Therapeutics commands a fully diluted market value of $598 million.
Sigilon Therapeutics plans to list on the Nasdaq under the symbol SGTX. Morgan Stanley, Jefferies, Barclays and Canaccord Genuity acted as lead managers on the deal.
